96 related articles for article (PubMed ID: 9145831)
1. Is Escherichia coli ATCC 25922 useful for monitoring broth microdilution tests of fluoroquinolones?
Fuchs PC; Barry AL; Brown SD
J Antimicrob Chemother; 1997 Apr; 39(4):549-50. PubMed ID: 9145831
[No Abstract] [Full Text] [Related]
2. In-vitro activity of OPC-17116 against bacterial enteric pathogens.
Arduino RC; Frosolono M; Murray BE
J Antimicrob Chemother; 1994 Sep; 34(3):403-7. PubMed ID: 7829414
[No Abstract] [Full Text] [Related]
3. [In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
Shimizu M; Tabata M; Hara T; Araake M; Watabe H; Nishino T
Jpn J Antibiot; 2002 Dec; 55(6):791-9. PubMed ID: 12621733
[TBL] [Abstract][Full Text] [Related]
4. In-vitro and in-vivo activities of DW-116, a new fluoroquinolone.
Choi KH; Hong JS; Kim SK; Lee DK; Yoon SJ; Choi EC
J Antimicrob Chemother; 1997 Apr; 39(4):509-14. PubMed ID: 9145824
[TBL] [Abstract][Full Text] [Related]
5. Bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions.
Cooper MA; Andrews JM; Wise R
J Antimicrob Chemother; 1991 Sep; 28(3):399-405. PubMed ID: 1660046
[TBL] [Abstract][Full Text] [Related]
6. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
Barry AL; Fuchs PC
J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
[TBL] [Abstract][Full Text] [Related]
7. In vitro antibacterial activity of enrofloxacin and ciprofloxacin in combination against Escherichia coli and staphylococcal clinical isolates from dogs.
Lautzenhiser SJ; Fialkowski JP; Bjorling D; Rosin E
Res Vet Sci; 2001 Jun; 70(3):239-41. PubMed ID: 11676620
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro activity of BAY Y 3118 with other fluoroquinolones.
Molinari G; Schito GC
Drugs; 1995; 49 Suppl 2():222-5. PubMed ID: 8549310
[No Abstract] [Full Text] [Related]
9. In-vitro slime production by Staphylococcus epidermidis in presence of subinhibitory concentrations of ciprofloxacin, ofloxacin and sparfloxacin.
Pérez-Giraldo C; Rodríguez-Benito A; Morán FJ; Hurtado C; Blanco MT; Gómez-García AC
J Antimicrob Chemother; 1994 Apr; 33(4):845-8. PubMed ID: 8056703
[No Abstract] [Full Text] [Related]
10. Interactions of the 4-quinolones with other antibacterials.
Lewin CS; Smith JT
J Med Microbiol; 1989 Jul; 29(3):221-7. PubMed ID: 2664184
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
Malmborg AS; Ahlén S
Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
[TBL] [Abstract][Full Text] [Related]
12. Anti-staphylococcal activity of temafloxacin, ciprofloxacin, ofloxacin and enoxacin.
Barry AL; Fuchs PC
J Antimicrob Chemother; 1991 Nov; 28(5):695-9. PubMed ID: 1663929
[TBL] [Abstract][Full Text] [Related]
13. Antibacterial activity of fluoroquinolones in combination with zidovudine.
Lewin CS; Allen RA; Amyes SG
J Med Microbiol; 1990 Oct; 33(2):127-31. PubMed ID: 2121991
[TBL] [Abstract][Full Text] [Related]
14. Postantibiotic effects of E-4868 and OPC-17116.
Sanford MD; Jones RN
J Antimicrob Chemother; 1993 Dec; 32(6):916-7. PubMed ID: 8144440
[No Abstract] [Full Text] [Related]
15. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Bauernfeind A
J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
[TBL] [Abstract][Full Text] [Related]
16. [Compared antibacterial activity of a new fluoroquinolone, sparfloxacin (AT 4140, RP 64206) and four other fluoroquinolones against 332 strains of enteropathogen bacteria].
Le Noc P; Croizé J; Le Noc D
Pathol Biol (Paris); 1993 Apr; 41(4):294-301. PubMed ID: 8233625
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility to ciprofloxacin of bacterial strains isolated from chronic otitis media and chronic sinusitis.
Gaillot O; Berche P
Drugs; 1995; 49 Suppl 2():200-2. PubMed ID: 8549303
[No Abstract] [Full Text] [Related]
18. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
[TBL] [Abstract][Full Text] [Related]
19. Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin, and ceftizoxime when using various National Committee for Clinical Laboratory Standards susceptibility test methods. Quality Control Study Group.
Bale MJ; Jones RN; Erwin ME
Diagn Microbiol Infect Dis; 1994 May; 19(1):65-8. PubMed ID: 7956017
[TBL] [Abstract][Full Text] [Related]
20. Effect of growth conditions on antimicrobial activity of DU-6859a and its bactericidal activity determined by the killing curve method.
Tanaka M; Hoshino K; Hohmura M; Ishida H; Kitamura A; Sato K; Hayakawa I; Nishino T
J Antimicrob Chemother; 1996 Jun; 37(6):1091-102. PubMed ID: 8836812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
